文献速递淋巴瘤造血干细胞移植与细胞治疗

地弗立肽预防嵌合抗原受体T细胞相关神经毒性综合征的2期试验

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.
PubMed 文献 · Blood Adv · 2023-01-01

这项2期研究评估地弗立肽预防复发/难治性大B细胞淋巴瘤患者接受阿基仑赛治疗后CAR-T相关神经毒性的安全性和疗效。Part 1确定2期推荐剂量为6.25 mg/kg;20例可评估患者中第30天神经毒性发生率约50%,低于ZUMA-1报告的64%。未报告意外安全性事件,但神经毒性降低幅度不太可能达到主要终点,研究提前终止。

要点

  • 地弗立肽2期推荐剂量为6.25 mg/kg,20例可评估患者第30天CAR-T相关神经毒性发生率约50%。
  • 该发生率低于ZUMA-1试验报告的64%,≥3级神经毒性中位事件持续时间为7天。
  • 未报告与地弗立肽相关的意外安全性发现或治疗中出现的不良事件或死亡。

核心结论

  • 地弗立肽使CAR-T相关神经毒性发生率及高级别神经毒性事件持续时间相对历史数据有适度降低,但降低幅度不太可能达到主要终点,研究提前终止。
  • 研究结果仍为CAR-T相关神经毒性的管理提供了有价值的潜在治疗启示。

研究设计与样本

  • 这是一项2期研究,评估地弗立肽预防接受阿基仑赛治疗的复发/难治性大B细胞淋巴瘤患者CAR-T相关神经毒性的安全性和疗效。
  • Part 1确定2期推荐剂量(RP2D)为6.25 mg/kg;来自Part 1和Part 2共20例接受RP2D的患者可评估疗效。
  • 主要终点为第30天CAR-T相关神经毒性发生率;试验注册号为NCT03954106。

主要发现

  • 第30天CAR-T相关神经毒性发生率约50%,低于ZUMA-1试验报告的64%。
  • ≥3级神经毒性的中位事件持续时间为7天。
  • 未报告与地弗立肽相关的意外安全性发现,也未报告与地弗立肽相关的治疗中出现的不良事件或死亡。
  • 地弗立肽使CAR-T相关神经毒性发生率和高级别神经毒性事件持续时间相对历史数据有适度降低。

关键数值与推荐

  • 地弗立肽2期推荐剂量(RP2D)为6.25 mg/kg。
  • 可评估疗效的患者为20例(来自Part 1和Part 2)接受RP2D者。
  • 第30天CAR-T相关神经毒性发生率约50%,ZUMA-1试验报告为64%。
  • ≥3级神经毒性的中位事件持续时间为7天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 降低幅度不太可能达到主要终点,研究提前终止。
  • 神经毒性发生率的降低是相对历史数据而言。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide was shown to reduce endothelial cell activation in vitro and is approved in the United States for treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT), and in the European Union for severe VOD/SOS after HCT in patients aged >1 month. Defibrotide may stabilize the endothelium during CAR-T therapy and reduce the rate of CAR-T-associated neurotoxicity. This phase 2 study evaluated the safety and efficacy of defibrotide for prevention of CAR-T-associated neurotoxicity in patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel. Part 1 established the recommended phase 2 dose (RP2D; 6.25 mg/kg); 20 patients (from parts 1 and 2) receiving the RP2D were evaluable for efficacy. Rate of CAR-T-associated neurotoxicity by day 30 (primary end point) was ∼50%, lower than reported in the ZUMA-1 trial (64%). Median event duration of grade ≥3 neurotoxicity was 7 days. No unexpected defibrotide-related safety findings and defibrotide-related treatment-emergent adverse events or deaths were reported. Results showed modest reduction in rate of CAR-T-associated neurotoxicity and high-grade neurotoxicity event duration relative to historical data; however, reduction was unlikely to meet the primary end point, so the study was terminated early. Nevertheless, results contribute valuable data for potential therapeutic insight on the management of CAR-T-associated neurotoxicity. This trial was registered at www.clinicaltrials.gov as #NCT03954106.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jacobson CA, Rosenthal AC, Arnason J, et al. A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome. Blood Adv. 2023. PMID: 37399456. doi:10.1182/bloodadvances.2023009961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。